GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Debt-to-EBITDA

NKGen Biotech (NKGen Biotech) Debt-to-EBITDA : -0.15 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

NKGen Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $9.99 Mil. NKGen Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $9.93 Mil. NKGen Biotech's annualized EBITDA for the quarter that ended in Dec. 2023 was $-131.44 Mil. NKGen Biotech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.15.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for NKGen Biotech's Debt-to-EBITDA or its related term are showing as below:

NKGN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.51   Med: -0.52   Max: -0.25
Current: -0.3

During the past 3 years, the highest Debt-to-EBITDA Ratio of NKGen Biotech was -0.25. The lowest was -2.51. And the median was -0.52.

NKGN's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs NKGN: -0.30

NKGen Biotech Debt-to-EBITDA Historical Data

The historical data trend for NKGen Biotech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Debt-to-EBITDA Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-EBITDA
-2.51 -0.52 -0.25

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Sep23 Dec23
Debt-to-EBITDA N/A - -0.50 -0.15 -0.15

Competitive Comparison of NKGen Biotech's Debt-to-EBITDA

For the Biotechnology subindustry, NKGen Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NKGen Biotech's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's Debt-to-EBITDA falls into.


NKGen Biotech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

NKGen Biotech's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9.991 + 9.93) / -80.999
=-0.25

NKGen Biotech's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9.991 + 9.93) / -131.444
=-0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

NKGen Biotech  (NAS:NKGN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

NKGen Biotech Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech (NKGen Biotech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Debt-to-EBITDA
Comparable Companies
OCUP CASI SPRO XLO NGM GBIO ASMB CCCC OCEA FIXX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
Website
https://www.nkgenbiotech.com
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.